[go: up one dir, main page]

AR010744A1 - CYCLOPHILINE POLYPROPYL INHIBITORS - Google Patents

CYCLOPHILINE POLYPROPYL INHIBITORS

Info

Publication number
AR010744A1
AR010744A1 ARP970105727A ARP970105727A AR010744A1 AR 010744 A1 AR010744 A1 AR 010744A1 AR P970105727 A ARP970105727 A AR P970105727A AR P970105727 A ARP970105727 A AR P970105727A AR 010744 A1 AR010744 A1 AR 010744A1
Authority
AR
Argentina
Prior art keywords
inhibitors
cyclophiline
polypropyl
enzymatic activity
cyclophilin
Prior art date
Application number
ARP970105727A
Other languages
Spanish (es)
Original Assignee
Guildford Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guildford Pharmaceuticals Inc filed Critical Guildford Pharmaceuticals Inc
Publication of AR010744A1 publication Critical patent/AR010744A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1024—Tetrapeptides with the first amino acid being heterocyclic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Trata de compuestos neurotroficos inhibidores de ciclofilina péptidos de moléculas pequenas y bajo peso molecular con una afinidad por inmunofilinasde tipo ciclofilina y su su como inhibidores de la actividad enzimética asociada conlas proteínas de inmunofilina, particularmente la actividadenzimética de la isomerasa peptidil-prolilo o rotamasa.It deals with neurotrophic compounds that inhibit cyclophilin peptides of small molecules and low molecular weight with an affinity for cyclophilin-like immunophilins and their su as inhibitors of the enzymatic activity associated with immunophilin proteins, particularly the enzymatic activity of peptidyl prolyl isomerase or rotamase.

ARP970105727A 1996-12-09 1997-12-05 CYCLOPHILINE POLYPROPYL INHIBITORS AR010744A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US76190296A 1996-12-09 1996-12-09

Publications (1)

Publication Number Publication Date
AR010744A1 true AR010744A1 (en) 2000-07-12

Family

ID=25063558

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970105727A AR010744A1 (en) 1996-12-09 1997-12-05 CYCLOPHILINE POLYPROPYL INHIBITORS

Country Status (8)

Country Link
EP (1) EP0966479A4 (en)
JP (1) JP2001505920A (en)
AR (1) AR010744A1 (en)
AU (1) AU5702698A (en)
CA (1) CA2263828A1 (en)
PA (1) PA8442401A1 (en)
WO (1) WO1998025950A1 (en)
ZA (1) ZA9710989B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU2901A (en) 1998-07-17 2004-05-12 Agouron Pharmaceuticals Inc. Compounds, compositions and methods for stimulating neuronal growth and elongation
US6809107B1 (en) 1999-07-09 2004-10-26 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic pyrrolidines and piperidines, and related compositions and methods
WO2001004090A2 (en) 1999-07-09 2001-01-18 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic tetrahydroisoquinolines and tetrahydrothienopyridines, and related compositions and methods
AU5483500A (en) 1999-07-09 2001-01-30 Ortho-Mcneil Pharmaceutical, Inc. Neurotrophic 2-azetidinecarboxylic acid derivatives, and related compositions and methods
SK11452002A3 (en) * 2000-02-11 2003-03-04 Vertex Pharmaceuticals Incorporated Piperazine and piperidine derivatives for treatment or prevention of neuronal damage
GB0030378D0 (en) 2000-12-13 2001-01-24 Cyclacel Ltd Compound
US6593362B2 (en) 2001-05-21 2003-07-15 Guilford Pharmaceuticals Inc. Non-peptidic cyclophilin binding compounds and their use
EP3164148A4 (en) 2014-06-25 2017-12-13 Cold Spring Harbor Laboratory Methods and compositions for inhibiting growth and epithelial to mesenchymal transition (emt) in cancer cells
KR102727918B1 (en) 2018-04-10 2024-11-11 사노피-아벤티스 도이칠란트 게엠베하 Synthesis of lixisenatide using capping

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023077A (en) * 1989-01-24 1991-06-11 Aphton Corporation Immunogenic compositions and methods for the treatment and prevention of gastric and duodenal ulcer disease
JP2782142B2 (en) * 1992-07-23 1998-07-30 カルピス株式会社 Angiotensin converting enzyme inhibitor and method for producing the same
IL106998A0 (en) * 1992-09-17 1993-12-28 Univ Florida Brain-enhanced delivery of neuroactive peptides by sequential metabolism
JP3089350B2 (en) * 1995-11-20 2000-09-18 ギルフォード ファーマシューティカルズ インコーポレイテッド Inhibitors of cyclophilin rotamase activity

Also Published As

Publication number Publication date
WO1998025950A1 (en) 1998-06-18
CA2263828A1 (en) 1998-06-18
AU5702698A (en) 1998-07-03
EP0966479A1 (en) 1999-12-29
EP0966479A4 (en) 2004-12-08
PA8442401A1 (en) 2000-05-24
ZA9710989B (en) 1999-05-25
JP2001505920A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
ES2131457B1 (en) SMALL INHIBITORS OF ROTAMASA ENZYMES ACTIVITY MOLECULES.
AR009749A1 (en) HETERO-CYCLIC ESTERS AND AMIDES, PHARMACEUTICAL COMPOSITIONS AND USE
EA199900182A1 (en) HETEROCYCLIC TIOESTERS AND KETONES
ES2138518A1 (en) Inhibitors of rotamase enzyme activity
ATE246510T1 (en) INHIBITORS OF CYCLOPHILIN ROTAMASE ACTIVITY
BRPI9611271A2 (en) rotamase enzyme activity inhibitors
MXPA99006120A (en) N-linked sulfonamides of heterocyclic thioesters.
TR200001644T2 (en) Small molecule inhibitors of rotamase enzyme activity
BRPI0607988A2 (en) compound, pharmaceutical composition, and method for inducing apoptosis in a cell
FR2808803B1 (en) MODIFIED ES CELLS AND SPECIFIC GENE OF ES CELLS
NZ316787A (en) Methods and compositions for the selective modification of nucleic acids
TW200611910A (en) Interferon-alpha polypeptides and conjugates
DE69942459D1 (en) ISOLATED NUCLEIC ACID MOLECULES COPYING T CELLS INDUCIBLE FACTORS (TIF), ENCODING PROTEINS AND THEIR USE
WO2005082341A3 (en) NON-PEPTIDYL AGENTS WITH pHSP20-LIKE ACTIVITY, AND USES THEREOF
GB9911047D0 (en) Assay method and means
ATE397084T1 (en) LENTIVIRAL PACKAGING CONSTRUCTS
AR010744A1 (en) CYCLOPHILINE POLYPROPYL INHIBITORS
NO20052363L (en) Interferon-alpha polypeptides and conjugates
AU3143897A (en) Oligonucleotides which specifically bind retroviral nucleocapsid proteins
WO2001049721A3 (en) Bacterial genes and proteins that are essential for cell viability and their uses
EA199900512A1 (en) N-BONDED SULPHONAMIDES OF HETEROCYCLIC TIOESTERS
WO2004070018A3 (en) Vegf-b and pdgf modulation of stem cells
DK0750637T3 (en) CAI resistance encoding a protein and its use
AR004113A1 (en) ROTAMASA ENZYME ACTIVITY INHIBITORS.
ECSP972273A (en) THIOESTERS AND HETERO CYCLIC KETONES

Legal Events

Date Code Title Description
FB Suspension of granting procedure